These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort. Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756 [TBL] [Abstract][Full Text] [Related]
4. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. Tonus C; Sellinger M; Koss K; Neupert G World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551 [TBL] [Abstract][Full Text] [Related]
6. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms. Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327 [TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. Tonus C; Neupert G; Sellinger M World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496 [TBL] [Abstract][Full Text] [Related]
8. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort. Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725 [TBL] [Abstract][Full Text] [Related]
9. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test. Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070 [TBL] [Abstract][Full Text] [Related]
10. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563 [TBL] [Abstract][Full Text] [Related]
11. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Haug U; Rothenbacher D; Wente MN; Seiler CM; Stegmaier C; Brenner H Br J Cancer; 2007 May; 96(9):1329-34. PubMed ID: 17406361 [TBL] [Abstract][Full Text] [Related]
12. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study. Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608 [TBL] [Abstract][Full Text] [Related]
13. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Haug U; Hundt S; Brenner H Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075 [TBL] [Abstract][Full Text] [Related]
14. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis. Nasir Kansestani A; Zare ME; Tong Q; Zhang J Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276 [TBL] [Abstract][Full Text] [Related]
15. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517 [TBL] [Abstract][Full Text] [Related]
16. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609 [TBL] [Abstract][Full Text] [Related]
18. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer. Ervens J; Fuchs H; Niemann VT; Hoffmeister B J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718 [TBL] [Abstract][Full Text] [Related]
19. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612 [TBL] [Abstract][Full Text] [Related]
20. [Comparison of different stool tests for the detection of cancer of the colon]. Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]